Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes

Cell Metabolism

Volumn 20, Issue 4, 2014, Pages 573-591

  Soccio, Raymond E ^a   Chen, Eric R ^a   Lazar, Mitchell A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; ANTIDIABETIC AGENT;

ADIPOSE TISSUE; BLADDER CANCER; CANCER RISK; CLINICAL STUDY; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIZATION; DRUG TARGETING; EDEMA; FLUID RETENTION; FRACTURE; HUMAN; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; REVIEW; WEIGHT GAIN; AGONISTS; ANIMAL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FRACTURES, BONE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; URINARY BLADDER NEOPLASMS;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EDEMA; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NON-ALCOHOLIC FATTY LIVER DISEASE; PPAR GAMMA; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84907990392     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2014.08.005     Document Type: Review

References (198)

1. ACOG Committee on Practice Bulletins - Gynecology ACOG Practice Bulletin No. 108: polycystic ovary syndrome Obstet. Gynecol. 114 2009 936 949
2. A.C. Adams, T. Coskun, C.C. Cheng, L.S. O'Farrell, S.L. Dubois, and A. Kharitonenkov Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones Mol. Metab. 2 2013 205 214
3. M. Ahmadian, J.M. Suh, N. Hah, C. Liddle, A.R. Atkins, M. Downes, and R.M. Evans PPARγ signaling and metabolism: the good, the bad and the future Nat. Med. 19 2013 557 566
4. A.A. Amato, S. Rajagopalan, J.Z. Lin, B.M. Carvalho, A.C.M. Figueira, J. Lu, S.D. Ayers, M. Mottin, R.L. Silveira, and P.C.T. Souza GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain J. Biol. Chem. 287 2012 28169 28179
5. American Diabetes Association Standards of medical care in diabetes - 2014 Diabetes Care 37 Suppl 1 2014 S14 S80
6. L. Azoulay, H. Yin, K.B. Filion, J. Assayag, A. Majdan, M.N. Pollak, and S. Suissa The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study BMJ 344 2012 e3645
7. R.G. Bach, M.M. Brooks, M. Lombardero, S. Genuth, T.W. Donner, A. Garber, L. Kennedy, E.S. Monrad, R. Pop-Busui, S.F. Kelsey, R.L. Frye BARI 2D Investigators Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial Circulation 128 2013 785 794
8. S. Bajare, J. Anthony, A. Nair, R. Marita, A. Damre, D. Patel, C. Rao, H. Sivaramakrishnan, and N. Deka Synthesis of N-(5-chloro-6-(quinolin-3-yloxy)pyridin-3-yl)benzenesulfonamide derivatives as non-TZD peroxisome proliferator-activated receptor γ (PPARγ) agonist Eur. J. Med. Chem. 58 2012 355 360
9. I. Barroso, M. Gurnell, V.E. Crowley, M. Agostini, J.W. Schwabe, M.A. Soos, G.L. Maslen, T.D. Williams, H. Lewis, and A.J. Schafer Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension Nature 402 1999 880 883
10. A. Basu, M.D. Jensen, F. McCann, D. Mukhopadhyay, M.J. Joyner, and R.A. Rizza Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes Diabetes Care 29 2006 510 514
11. G.R. Beck Jr., N.B. Khazai, G.F. Bouloux, C.E. Camalier, Y. Lin, L.M. Garneys, J. Siqueira, L. Peng, F. Pasquel, and D. Umpierrez The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes Transl. Res. 161 2013 145 155
12. R. Belfort, S.A. Harrison, K. Brown, C. Darland, J. Finch, J. Hardies, B. Balas, A. Gastaldelli, F. Tio, and J. Pulcini A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N. Engl. J. Med. 355 2006 2297 2307
13. J. Bełtowski, J. Rachańczyk, and M. Włodarczyk Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms PPAR Res. 2013 2013 628628
14. R. Berria, L. Glass, A. Mahankali, Y. Miyazaki, A. Monroy, E. De Filippis, K. Cusi, E. Cersosimo, R.A. Defronzo, and A. Gastaldelli Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus Clin. Pharmacol. Ther. 82 2007 275 281
15. C.W. Bolten, P.M. Blanner, W.G. McDonald, N.R. Staten, R.A. Mazzarella, G.B. Arhancet, M.F. Meier, D.J. Weiss, P.M. Sullivan, and A.E. Hromockyj Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma Gene Regul. Syst. Bio. 1 2007 73 82
16. M.A. Bouhlel, B. Derudas, E. Rigamonti, R. Dièvart, J. Brozek, S. Haulon, C. Zawadzki, B. Jude, G. Torpier, and N. Marx PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties Cell Metab. 6 2007 137 143
17. C.A. Brauer, M. Coca-Perraillon, D.M. Cutler, and A.B. Rosen Incidence and mortality of hip fractures in the United States JAMA 302 2009 1573 1579
18. G.A. Bray, S.R. Smith, M.A. Banerji, D. Tripathy, S.C. Clement, T.A. Buchanan, R.R. Henry, A.E. Kitabchi, S. Mudaliar, and N. Musi Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial Diabetes Obes. Metab. 15 2013 931 937
19. K.K. Brown, B.R. Henke, S.G. Blanchard, J.E. Cobb, R. Mook, I. Kaldor, S.A. Kliewer, J.M. Lehmann, J.M. Lenhard, and W.W. Harrington A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat Diabetes 48 1999 1415 1424
20. CDC (2010). FASTSTATS - Deaths and Mortality. http://www.cdc.gov/nchs/fastats/deaths.htm.
21. CDC More than 29 million Americans have diabetes; 1 in 4 doesn't know 2014 Press Release, CDC Online Newsroom
22. N. Chalasani, Z. Younossi, J.E. Lavine, A.M. Diehl, E.M. Brunt, K. Cusi, M. Charlton, and A.J. Sanyal The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 55 2012 2005 2023
23. L. Chang, L. Villacorta, R. Li, M. Hamblin, W. Xu, C. Dou, J. Zhang, J. Wu, R. Zeng, and Y.E. Chen Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor-γ deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis Circulation 126 2012 1067 1078
24. L. Chao, B. Marcus-Samuels, M.M. Mason, J. Moitra, C. Vinson, E. Arioglu, O. Gavrilova, and M.L. Reitman Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones J. Clin. Invest. 106 2000 1221 1228
25. A. Chawla, E.J. Schwarz, D.D. Dimaculangan, and M.A. Lazar Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation Endocrinology 135 1994 798 800
26. Z. Chen, P.A. Vigueira, K.T. Chambers, A.M. Hall, M.S. Mitra, N. Qi, W.G. McDonald, J.R. Colca, R.F. Kletzien, and B.N. Finck Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione J. Biol. Chem. 287 2012 23537 23548
27. E. Chiquette, G. Ramirez, and R. Defronzo A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors Arch. Intern. Med. 164 2004 2097 2104
28. J.H. Choi, A.S. Banks, J.L. Estall, S. Kajimura, P. Boström, D. Laznik, J.L. Ruas, M.J. Chalmers, T.M. Kamenecka, and M. Blüher Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5 Nature 466 2010 451 456
29. J.H. Choi, A.S. Banks, T.M. Kamenecka, S.A. Busby, M.J. Chalmers, N. Kumar, D.S. Kuruvilla, Y. Shin, Y. He, and J.B. Bruning Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation Nature 477 2011 477 481
30. D. Cipolletta, M. Feuerer, A. Li, N. Kamei, J. Lee, S.E. Shoelson, C. Benoist, and D. Mathis PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells Nature 486 2012 549 553
31. M. Claussnitzer, S.N. Dankel, B. Klocke, H. Grallert, V. Glunk, T. Berulava, H. Lee, N. Oskolkov, J. Fadista, K. Ehlers DIAGRAM+Consortium Leveraging cross-species transcription factor binding site patterns: from diabetes risk loci to disease mechanisms Cell 156 2014 343 358
32. J.R. Colca, W.G. McDonald, G.S. Cavey, S.L. Cole, D.D. Holewa, A.S. Brightwell-Conrad, C.L. Wolfe, J.S. Wheeler, K.R. Coulter, and P.M. Kilkuskie Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT) - relationship to newly identified mitochondrial pyruvate carrier proteins PLoS ONE 8 2013 e61551
33. J.R. Colca, J.T. VanderLugt, W.J. Adams, A. Shashlo, W.G. McDonald, J. Liang, R. Zhou, and D.G. Orloff Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer Clin. Pharmacol. Ther. 93 2013 352 359
34. H.M. Colhoun, S.J. Livingstone, H.C. Looker, A.D. Morris, S.H. Wild, R.S. Lindsay, C. Reed, P.T. Donnan, B. Guthrie, G.P. Leese Scottish Diabetes Research Network Epidemiology Group Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs Diabetologia 55 2012 2929 2937
35. I.N. Colmers, S.L. Bowker, S.R. Majumdar, and J.A. Johnson Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis CMAJ 184 2012 E675 E683
36. I.N. Colmers, S.L. Bowker, and J.A. Johnson Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis Diabetes Metab. 38 2012 475 484
37. M.A. Deeg, J.B. Buse, R.B. Goldberg, D.M. Kendall, A.J. Zagar, S.J. Jacober, M.A. Khan, A.T. Perez, M.H. Tan GLAI Study Investigators Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia Diabetes Care 30 2007 2458 2464
38. R.A. DeFronzo Pathogenesis of type 2 diabetes mellitus Med. Clin. North Am. 88 2004 787 835 ix
39. R.A. DeFronzo, D. Tripathy, D.C. Schwenke, M. Banerji, G.A. Bray, T.A. Buchanan, S.C. Clement, R.R. Henry, H.N. Hodis, A.E. Kitabchi ACT NOW Study Pioglitazone for diabetes prevention in impaired glucose tolerance N. Engl. J. Med. 364 2011 1104 1115
40. DePaoli, A.M., Higgins, L.S., Henry, R.R., Mantzoros, C., and Dunn, F.L. (2014). Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care DC-132480.
41. J.P. Després, B. Lamarche, P. Mauriège, B. Cantin, G.R. Dagenais, S. Moorjani, and P.J. Lupien Hyperinsulinemia as an independent risk factor for ischemic heart disease N. Engl. J. Med. 334 1996 952 957
42. A.S. Divakaruni, S.E. Wiley, G.W. Rogers, A.Y. Andreyev, S. Petrosyan, M. Loviscach, E.A. Wall, N. Yadava, A.P. Heuck, and D.A. Ferrick Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier Proc. Natl. Acad. Sci. USA 110 2013 5422 5427
43. W. Doehner, E. Erdmann, R. Cairns, A.L. Clark, J.A. Dormandy, E. Ferrannini, and S.D. Anker Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population Int. J. Cardiol. 162 2012 20 26
44. J.A. Dormandy, B. Charbonnel, D.J.A. Eckland, E. Erdmann, M. Massi-Benedetti, I.K. Moules, A.M. Skene, M.H. Tan, P.J. Lefèbvre, G.D. Murray PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
45. S.Z. Duan, C.Y. Ivashchenko, M.W. Russell, D.S. Milstone, and R.M. Mortensen Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice Circ. Res. 97 2005 372 379
46. P.A. Dutchak, T. Katafuchi, A.L. Bookout, J.H. Choi, R.T. Yu, D.J. Mangelsdorf, and S.A. Kliewer Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones Cell 148 2012 556 567
47. E. Erdmann, J.A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I.K. Moules, A.M. Skene PROactive Investigators The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study J. Am. Coll. Cardiol. 49 2007 1772 1780
48. E. Erdmann, E. Song, R. Spanheimer, A.-R. van Troostenburg de Bruyn, and A. Perez Observational follow-up of the PROactive study: a 6-year update Diabetes Obes. Metab. 16 2014 63 74
49. F.S. Facchini, N. Hua, F. Abbasi, and G.M. Reaven Insulin resistance as a predictor of age-related diseases J. Clin. Endocrinol. Metab. 86 2001 3574 3578
50. J.-L. Faillie, P. Petit, J.-L. Montastruc, and D. Hillaire-Buys Scientific evidence and controversies about pioglitazone and bladder cancer: which lessons can be drawn? Drug Saf. 36 2013 693 707
51. FDA (2013). Press announcements - FDA requires removal of certain restrictions on the diabetes drug Avandia.
52. D.L. Feinstein, A. Spagnolo, C. Akar, G. Weinberg, P. Murphy, V. Gavrilyuk, and C. Dello Russo Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. 70 2005 177 188
53. A. Ferrara, J.D. Lewis, C.P. Quesenberry Jr., T. Peng, B.L. Strom, S.K. Van Den Eeden, S.F. Ehrlich, and L.A. Habel Cohort study of pioglitazone and cancer incidence in patients with diabetes Diabetes Care 34 2011 923 929
54. M. Ferwana, B. Firwana, R. Hasan, M.H. Al-Mallah, S. Kim, V.M. Montori, and M.H. Murad Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies Diabet. Med. 30 2013 1026 1032
55. B. Finan, B. Yang, N. Ottaway, K. Stemmer, T.D. Müller, C.-X. Yi, K. Habegger, S.C. Schriever, C. García-Cáceres, and D.G. Kabra Targeted estrogen delivery reverses the metabolic syndrome Nat. Med. 18 2012 1847 1856
56. C.G. Fiorenza, S.H. Chou, and C.S. Mantzoros Lipodystrophy: pathophysiology and advances in treatment Nat. Rev. Endocrinol. 7 2011 137 150
57. Z.E. Floyd, and J.M. Stephens Control of peroxisome proliferator-activated receptor gamma2 stability and activity by SUMOylation Obes. Res. 12 2004 921 928
58. T. Fujita, Y. Sugiyama, S. Taketomi, T. Sohda, Y. Kawamatsu, H. Iwatsuka, and Z. Suzuoki Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent Diabetes 32 1983 804 810
59. E.A.M. Gale Is type 2 diabetes a category error? Lancet 381 2013 1956 1957
60. E.J. Gallagher, and D. LeRoith Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer Diabetes Care 36 Suppl 2 2013 S233 S239
61. O. Gavrilova, M. Haluzik, K. Matsusue, J.J. Cutson, L. Johnson, K.R. Dietz, C.J. Nicol, C. Vinson, F.J. Gonzalez, and M.L. Reitman Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass J. Biol. Chem. 278 2003 34268 34276
62. H.C. Gerstein, S. Yusuf, J. Bosch, J. Pogue, P. Sheridan, N. Dinccag, M. Hanefeld, B. Hoogwerf, M. Laakso, V. Mohan DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 368 2006 1096 1105
63. H.N. Gouda, G.S. Sagoo, A.-H. Harding, J. Yates, M.S. Sandhu, and J.P.T. Higgins The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis Am. J. Epidemiol. 171 2010 645 655
64. R. Govindarajan, L. Ratnasinghe, D.L. Simmons, E.R. Siegel, M.V. Midathada, L. Kim, P.J. Kim, R.J. Owens, and N.P. Lang Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes J. Clin. Oncol. 25 2007 1476 1481
65. D.J. Graham, R. Ouellet-Hellstrom, T.E. MaCurdy, F. Ali, C. Sholley, C. Worrall, and J.A. Kelman Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone JAMA 304 2010 411 418
66. F.M. Gregoire, F. Zhang, H.J. Clarke, T.A. Gustafson, D.D. Sears, S. Favelyukis, J. Lenhard, D. Rentzeperis, L.E. Clemens, Y. Mu, and B.E. Lavan MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema Mol. Endocrinol. 23 2009 975 988
67. A. Grey Thiazolidinedione-induced skeletal fragility - mechanisms and implications Diabetes Obes. Metab. 11 2009 275 284
68. Y. Guan, C. Hao, D.R. Cha, R. Rao, W. Lu, D.E. Kohan, M.A. Magnuson, R. Redha, Y. Zhang, and M.D. Breyer Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption Nat. Med. 11 2005 861 866
69. A.K. Haakonsson, M. Stahl Madsen, R. Nielsen, A. Sandelin, and S. Mandrup Acute genome-wide effects of rosiglitazone on PPARγ transcriptional networks in adipocytes Mol. Endocrinol. 27 2013 1536 1549
70. C. Hadigan, S. Yawetz, A. Thomas, F. Havers, P.E. Sax, and S. Grinspoon Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial Ann. Intern. Med. 140 2004 786 794
71. V. Hainer, H. Toplak, and A. Mitrakou Treatment modalities of obesity: what fits whom? Diabetes Care 31 Suppl 2 2008 S269 S277
72. N. Halberg, I. Wernstedt-Asterholm, and P.E. Scherer The adipocyte as an endocrine cell Endocrinol. Metab. Clin. North Am. 37 2008 753 768 x-xi
73. M. Hamblin, L. Chang, H. Zhang, K. Yang, J. Zhang, and Y.E. Chen Vascular smooth muscle cell peroxisome proliferator-activated receptor-γ mediates pioglitazone-reduced vascular lesion formation Arterioscler. Thromb. Vasc. Biol. 31 2011 352 359
74. C. Hampp, V. Borders-Hemphill, D.G. Moeny, and D.K. Wysowski Use of antidiabetic drugs in the U.S., 2003-2012 Diabetes Care 37 2014 1367 1374
75. D.G. Hardie AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease J. Intern. Med. 2014 10.1111/joim.12268
76. T. Harsløf, L. Wamberg, L. Møller, H. Stødkilde-Jørgensen, S. Ringgaard, S.B. Pedersen, and B.L. Langdahl Rosiglitazone decreases bone mass and bone marrow fat J. Clin. Endocrinol. Metab. 96 2011 1541 1548
77. S. Hauser, G. Adelmant, P. Sarraf, H.M. Wright, E. Mueller, and B.M. Spiegelman Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation J. Biol. Chem. 275 2000 18527 18533
78. W. He, Y. Barak, A. Hevener, P. Olson, D. Liao, J. Le, M. Nelson, E. Ong, J.M. Olefsky, and R.M. Evans Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle Proc. Natl. Acad. Sci. USA 100 2003 15712 15717
79. H. He, H. Tao, H. Xiong, S.Z. Duan, F.X. McGowan Jr., R.M. Mortensen, and J.A. Balschi Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse hearts Toxicol. Sci. 138 2014 468 481
80. K. Henriksen, I. Byrjalsen, R.H. Nielsen, A.N. Madsen, L.K. Larsen, C. Christiansen, H. Beck-Nielsen, and M.A. Karsdal A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats Eur. J. Pharmacol. 616 2009 340 345
81. K. Henriksen, I. Byrjalsen, P. Qvist, H. Beck-Nielsen, G. Hansen, B.J. Riis, H. Perrild, O.L. Svendsen, J. Gram, M.A. Karsdal, C. Christiansen BALLET Trial Investigators Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy Diabetes Metab. Res. Rev. 27 2011 392 401
82. A.L. Hevener, W. He, Y. Barak, J. Le, G. Bandyopadhyay, P. Olson, J. Wilkes, R.M. Evans, and J. Olefsky Muscle-specific Pparg deletion causes insulin resistance Nat. Med. 9 2003 1491 1497
83. A.L. Hevener, J.M. Olefsky, D. Reichart, M.T.A. Nguyen, G. Bandyopadyhay, H.-Y. Leung, M.J. Watt, C. Benner, M.A. Febbraio, and A.-K. Nguyen Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones J. Clin. Invest. 117 2007 1658 1669
84. D. Hillaire-Buys, J.-L. Faillie, and J.-L. Montastruc Pioglitazone and bladder cancer Lancet 378 2011 1543 1544 author reply 1544-1545
85. P.D. Home, S.J. Pocock, H. Beck-Nielsen, R. Gomis, M. Hanefeld, N.P. Jones, M. Komajda, J.J.V. McMurray RECORD Study Group Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis N. Engl. J. Med. 357 2007 28 38
86. P.D. Home, S.J. Pocock, H. Beck-Nielsen, P.S. Curtis, R. Gomis, M. Hanefeld, N.P. Jones, M. Komajda, J.J.V. McMurray RECORD Study Team Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135
87. T. Horio, M. Suzuki, K. Suzuki, I. Takamisawa, A. Hiuge, K. Kamide, S. Takiuchi, Y. Iwashima, S. Kihara, and T. Funahashi Pioglitazone improves left ventricular diastolic function in patients with essential hypertension Am. J. Hypertens. 18 2005 949 957
88. E. Hu, J.B. Kim, P. Sarraf, and B.M. Spiegelman Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma Science 274 1996 2100 2103
89. T.S. Hughes, P.K. Giri, I.M.S. de Vera, D.P. Marciano, D.S. Kuruvilla, Y. Shin, A.-L. Blayo, T.M. Kamenecka, T.P. Burris, P.R. Griffin, and D.J. Kojetin An alternate binding site for PPARγ ligands Nat. Commun. 5 2014 3571
90. I. Iankova, R.K. Petersen, J.-S. Annicotte, C. Chavey, J.B. Hansen, I. Kratchmarova, D. Sarruf, M. Benkirane, K. Kristiansen, and L. Fajas Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis Mol. Endocrinol. 20 2006 1494 1505
91. I. Idris, G. Warren, and R. Donnelly Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes Arch. Intern. Med. 172 2012 1005 1011
92. R.H. Jani, V. Pai, P. Jha, G. Jariwala, S. Mukhopadhyay, A. Bhansali, and S. Joshi A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI) Diabetes Technol. Ther. 16 2014 63 71
93. S. Ji, S.Y. Park, J. Roth, H.S. Kim, and J.W. Cho O-GlcNAc modification of PPARγ reduces its transcriptional activity Biochem. Biophys. Res. Commun. 417 2012 1158 1163
94. X. Jiang, X. Ye, W. Guo, H. Lu, and Z. Gao Inhibition of HDAC3 promotes ligand-independent PPARgamma activation by protein acetylation J. Mol. Endocrinol. 2014 10.1530/JME-14-0066
95. S.A. Jones, L.B. Moore, J.L. Shenk, G.B. Wisely, G.A. Hamilton, D.D. McKee, N.C. Tomkinson, E.L. LeCluyse, M.H. Lambert, and T.M. Willson The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution Mol. Endocrinol. 14 2000 27 39
96. J.W. Jonker, J.M. Suh, A.R. Atkins, M. Ahmadian, P. Li, J. Whyte, M. He, H. Juguilon, Y.-Q. Yin, and C.T. Phillips A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis Nature 485 2012 391 394
97. B.B. Kahn, and T.E. McGraw Rosiglitazone, PPARγ, and type 2 diabetes N. Engl. J. Med. 363 2010 2667 2669
98. S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones, B.G. Kravitz, J.M. Lachin, M.C. O'Neill, B. Zinman, G. Viberti ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N. Engl. J. Med. 355 2006 2427 2443
99. S.E. Kahn, B. Zinman, J.M. Lachin, S.M. Haffner, W.H. Herman, R.R. Holman, B.G. Kravitz, D. Yu, M.A. Heise, R.P. Aftring, G. Viberti Diabetes Outcome Progression Trial (ADOPT) Study Group Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT) Diabetes Care 31 2008 845 851
100. G.E. Kilroy, X. Zhang, and Z.E. Floyd PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal Obesity (Silver Spring) 17 2009 665 673
101. G. Kilroy, H. Kirk-Ballard, L.E. Carter, and Z.E. Floyd The ubiquitin ligase Siah2 regulates PPARγ activity in adipocytes Endocrinology 153 2012 1206 1218
102. J.K. Kim, J.J. Fillmore, O. Gavrilova, L. Chao, T. Higashimori, H. Choi, H.-J. Kim, C. Yu, Y. Chen, and X. Qu Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice Diabetes 52 2003 1311 1318
103. W.C. Knowler, R.F. Hamman, S.L. Edelstein, E. Barrett-Connor, D.A. Ehrmann, E.A. Walker, S.E. Fowler, D.M. Nathan, S.E. Kahn Diabetes Prevention Program Research Group Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program Diabetes 54 2005 1150 1156
104. J. Kohlroser, J. Mathai, J. Reichheld, B.F. Banner, and H.L. Bonkovsky Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration Am. J. Gastroenterol. 95 2000 272 276
105. C. Koro, S. Barrett, and N. Qizilbash Cancer risks in thiazolidinedione users compared to other anti-diabetic agents Pharmacoepidemiol. Drug Saf. 16 2007 485 492
106. J.Y. Krzeszinski, W. Wei, H. Huynh, Z. Jin, X. Wang, T.-C. Chang, X.-J. Xie, L. He, L.S. Mangala, and G. Lopez-Berestein miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2 Nature 2014 10.1038/nature13375
107. R.M. Lago, P.P. Singh, and R.W. Nesto Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials Lancet 370 2007 1129 1136
108. I. Leal, S.A. Romio, M. Schuemie, A. Oteri, M. Sturkenboom, and G. Trifirò Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone Br. J. Clin. Pharmacol. 75 2013 861 868
109. N.K. LeBrasseur, M. Kelly, T.-S. Tsao, S.R. Farmer, A.K. Saha, N.B. Ruderman, and E. Tomas Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues Am. J. Physiol. Endocrinol. Metab. 291 2006 E175 E181
110. M.I. Lefterova, A.K. Haakonsson, M.A. Lazar, and S. Mandrup PPARγ and the global map of adipogenesis and beyond Trends Endocrinol. Metab. 25 2014 293 302
111. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J. Biol. Chem. 270 1995 12953 12956
112. M. Lehrke, and M.A. Lazar The many faces of PPARgamma Cell 123 2005 993 999
113. M. Lemoine, L. Serfaty, P. Cervera, J. Capeau, and V. Ratziu Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage Hepatol. Res. 2013 10.1111/hepr.12244
114. J.D. Lewis, A. Ferrara, T. Peng, M. Hedderson, W.B. Bilker, C.P. Quesenberry Jr., D.J. Vaughn, L. Nessel, J. Selby, and B.L. Strom Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 34 2011 916 922
115. J.D. Lewis, L. Habel, C. Quesenberry, R. Mamtani, T. Peng, W.B. Bilker, M. Hedderson, L. Nessel, D.J. Vaughn, B.L. Strom, and A. Ferrara Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer Pharmacoepidemiol. Drug Saf. 23 2014 636 645
116. A.C. Li, K.K. Brown, M.J. Silvestre, T.M. Willson, W. Palinski, and C.K. Glass Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J. Clin. Invest. 106 2000 523 531
117. P. Li, W. Fan, J. Xu, M. Lu, H. Yamamoto, J. Auwerx, D.D. Sears, S. Talukdar, D. Oh, and A. Chen Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances PPARγ activity and insulin sensitivity Cell 147 2011 815 826
118. M.-Y. Li, A.W.Y. Kong, H. Yuan, L.T. Ma, M.K.Y. Hsin, I.Y.P. Wan, M.J. Underwood, and G.G. Chen Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice Curr. Cancer Drug Targets 12 2012 597 606
119. A.M. Lincoff, K. Wolski, S.J. Nicholls, and S.E. Nissen Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 2007 1180 1188
120. A.M. Lincoff, J.-C. Tardif, G.G. Schwartz, S.J. Nicholls, L. Rydén, B. Neal, K. Malmberg, H. Wedel, J.B. Buse, R.R. Henry AleCardio Investigators Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial JAMA 311 2014 1515 1525
121. R. Lomonaco, C. Ortiz-Lopez, B. Orsak, A. Webb, J. Hardies, C. Darland, J. Finch, A. Gastaldelli, S. Harrison, F. Tio, and K. Cusi Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease Hepatology 55 2012 1389 1397
122. R. Lomonaco, N.E. Sunny, F. Bril, and K. Cusi Nonalcoholic fatty liver disease: current issues and novel treatment approaches Drugs 73 2013 1 14
123. M. Lu, D.A. Sarruf, S. Talukdar, S. Sharma, P. Li, G. Bandyopadhyay, S. Nalbandian, W. Fan, J.R. Gayen, and S.K. Mahata Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones Nat. Med. 17 2011 618 622
124. D.S. Ludwig, and M.I. Friedman Increasing adiposity: consequence or cause of overeating? JAMA 311 2014 2167 2168
125. K.W. Mahaffey, G. Hafley, S. Dickerson, S. Burns, S. Tourt-Uhlig, J. White, L.K. Newby, M. Komajda, J. McMurray, and R. Bigelow Results of a reevaluation of cardiovascular outcomes in the RECORD trial Am. Heart J. 166 2013 240 249
126. R. Marfella, M. Portoghese, F. Ferraraccio, M. Siniscalchi, M. Babieri, C. Di Filippo, M. D'Amico, F. Rossi, and G. Paolisso Thiazolidinediones may contribute to the intramyocardial lipid accumulation in diabetic myocardium: effects on cardiac function Heart 95 2009 1020 1022
127. T. Mazzone, P.M. Meyer, S.B. Feinstein, M.H. Davidson, G.T. Kondos, R.B. D'Agostino Sr., A. Perez, J.-C. Provost, and S.M. Haffner Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2006 2572 2581
128. A.E. Mehran, N.M. Templeman, G.S. Brigidi, G.E. Lim, K.-Y. Chu, X. Hu, J.D. Botezelli, A. Asadi, B.G. Hoffman, and T.J. Kieffer Hyperinsulinemia drives diet-induced obesity independently of brain insulin production Cell Metab. 16 2012 723 737
129. Y. Miyazaki, E.D. Filippis, M. Bajaj, E. Wajcberg, L. Glass, C. Triplitt, E. Cersosimo, L.J. Mandarino, and R.A. Defronzo Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician Br. J. Diabetes Vasc. Dis. 5 2005 28 35
130. D.D. Moore "No, really, how do they work?" Genes Dev. 19 2005 413 414
131. A. Natali, and E. Ferrannini Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review Diabetologia 49 2006 434 441
132. National Program of Cancer Registries United States Cancer Statistics (USCS) (2006-2010).
133. A.R. Nawrocki, M.W. Rajala, E. Tomas, U.B. Pajvani, A.K. Saha, M.E. Trumbauer, Z. Pang, A.S. Chen, N.B. Ruderman, and H. Chen Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists J. Biol. Chem. 281 2006 2654 2660
134. R.W. Nesto, D. Bell, R.O. Bonow, V. Fonseca, S.M. Grundy, E.S. Horton, M. Le Winter, D. Porte, C.F. Semenkovich, and S. Smith Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 27 2004 256 263
135. A. Neumann, A. Weill, P. Ricordeau, J.P. Fagot, F. Alla, and H. Allemand Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study Diabetologia 55 2012 1953 1962
136. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 356 2007 2457 2471
137. S.E. Nissen, and K. Wolski Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality Arch. Intern. Med. 170 2010 1191 1201
138. S.E. Nissen, S.J. Nicholls, K. Wolski, R. Nesto, S. Kupfer, A. Perez, H. Jure, R. De Larochellière, C.S. Staniloae, K. Mavromatis PERISCOPE Investigators Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial JAMA 299 2008 1561 1573
139. A.W. Norris, L. Chen, S.J. Fisher, I. Szanto, M. Ristow, A.C. Jozsi, M.F. Hirshman, E.D. Rosen, L.J. Goodyear, and F.J. Gonzalez Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones J. Clin. Invest. 112 2003 608 618
140. J.I. Odegaard, R.R. Ricardo-Gonzalez, M.H. Goforth, C.R. Morel, V. Subramanian, L. Mukundan, A. Red Eagle, D. Vats, F. Brombacher, A.W. Ferrante, and A. Chawla Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance Nature 447 2007 1116 1120
141. L. Oei, M.C. Zillikens, A. Dehghan, G.H.S. Buitendijk, M.C. Castaño-Betancourt, K. Estrada, L. Stolk, E.H.G. Oei, J.B.J. van Meurs, and J.A.M.J.L. Janssen High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study Diabetes Care 36 2013 1619 1628
142. H. Ohno, K. Shinoda, B.M. Spiegelman, and S. Kajimura PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein Cell Metab. 15 2012 395 404
143. T. Ohshima, H. Koga, and K. Shimotohno Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification J. Biol. Chem. 279 2004 29551 29557
144. G. Pascual, A.L. Fong, S. Ogawa, A. Gamliel, A.C. Li, V. Perissi, D.W. Rose, T.M. Willson, M.G. Rosenfeld, and C.K. Glass A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma Nature 437 2005 759 763
145. C. Piccinni, D. Motola, G. Marchesini, and E. Poluzzi Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting Diabetes Care 34 2011 1369 1371
146. X. Prieur, C.Y.L. Mok, V.R. Velagapudi, V. Núñez, L. Fuentes, D. Montaner, K. Ishikawa, A. Camacho, N. Barbarroja, and S. O'Rahilly Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice Diabetes 60 2011 797 809
147. Z. Punthakee, J. Bosch, G. Dagenais, R. Diaz, R. Holman, J.L. Probstfield, A. Ramachandran, M.C. Riddle, L.E. Rydén, B. Zinman TIDE Trial Investigators Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial Diabetologia 55 2012 36 45
148. Z. Punthakee, N. Alméras, J.-P. Després, G.R. Dagenais, S.S. Anand, D.L. Hunt, A.M. Sharma, H. Jung, S. Yusuf, and H.C. Gerstein Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial Diabet. Med. 31 2014 1086 1092
149. L. Qiang, L. Wang, N. Kon, W. Zhao, S. Lee, Y. Zhang, M. Rosenbaum, Y. Zhao, W. Gu, S.R. Farmer, and D. Accili Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ Cell 150 2012 620 632
150. S.M. Rangwala, and M.A. Lazar The dawn of the SPPARMs? Sci. STKE 2002 2002 pe9
151. S.M. Rangwala, B. Rhoades, J.S. Shapiro, A.S. Rich, J.K. Kim, G.I. Shulman, K.H. Kaestner, and M.A. Lazar Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity Dev. Cell 5 2003 657 663
152. V. Ratziu, F. Charlotte, C. Bernhardt, P. Giral, M. Halbron, G. Lenaour, A. Hartmann-Heurtier, E. Bruckert, T. Poynard LIDO Study Group Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial Hepatology 51 2010 445 453
153. N.S.B. Rawson Review of the quality of observational studies of the association between rosiglitazone and acute myocardial infarction J. Popul. Ther. Clin. Pharmacol. 21 2014 e214 e232
154. G.M. Reaven Banting lecture 1988. Role of insulin resistance in human disease Diabetes 37 1988 1595 1607
155. N. Riera-Guardia, and D. Rothenbacher The effect of thiazolidinediones on adiponectin serum level: a meta-analysis Diabetes Obes. Metab. 10 2008 367 375
156. G.T. Robbins, and D. Nie PPAR gamma, bioactive lipids, and cancer progression Front. Biosci. (Landmark Ed.) 17 2012 1816 1834
157. E.D. Rosen, R.N. Kulkarni, P. Sarraf, U. Ozcan, T. Okada, C.-H. Hsu, D. Eisenman, M.A. Magnuson, F.J. Gonzalez, C.R. Kahn, and B.M. Spiegelman Targeted elimination of peroxisome proliferator-activated receptor γ in β cells leads to abnormalities in islet mass without compromising glucose homeostasis Mol. Cell. Biol. 23 2003 7222 7229
158. C.L. Roumie, R.A. Greevy, C.G. Grijalva, A.M. Hung, X. Liu, H.J. Murff, T.A. Elasy, and M.R. Griffin Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes JAMA 311 2014 2288 2296
159. M. Rubin, J. Manavalan, S. Agarwal, D. McMahon, A. Nino, L.A. Fitzpatrick, and J. Bilezikian Effects of Rosiglitazone vs Metformin on Circulating Osteoclast and Osteogenic Precursor Cells in Postmenopausal Women with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab. 2014 10.1210/jc.2013-3666 Published online June 6, 2014
160. K.K. Ryan, B. Li, B.E. Grayson, E.K. Matter, S.C. Woods, and R.J. Seeley A role for central nervous system PPAR-γ in the regulation of energy balance Nat. Med. 17 2011 623 626
161. J. Sakamoto, H. Kimura, S. Moriyama, H. Odaka, Y. Momose, Y. Sugiyama, and H. Sawada Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone Biochem. Biophys. Res. Commun. 278 2000 704 711
162. C. Sambanis, K. Tziomalos, E. Kountana, N. Kakavas, I. Zografou, A. Balaska, G. Koulas, A. Karagiannis, and C. Zamboulis Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes Acta Diabetol. 45 2008 23 30
163. V.T. Samuel, K.F. Petersen, and G.I. Shulman Lipid-induced insulin resistance: unravelling the mechanism Lancet 375 2010 2267 2277
164. A.J. Sanyal, N. Chalasani, K.V. Kowdley, A. McCullough, A.M. Diehl, N.M. Bass, B.A. Neuschwander-Tetri, J.E. Lavine, J. Tonascia, A. Unalp NASH CRN Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N. Engl. J. Med. 362 2010 1675 1685
165. A. Saremi, D.C. Schwenke, T.A. Buchanan, H.N. Hodis, W.J. Mack, M. Banerji, G.A. Bray, S.C. Clement, R.R. Henry, and A.E. Kitabchi Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors Arterioscler. Thromb. Vasc. Biol. 33 2013 393 399
166. D.A. Sarruf, F. Yu, H.T. Nguyen, D.L. Williams, R.L. Printz, K.D. Niswender, and M.W. Schwartz Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis Endocrinology 150 2009 707 712
167. K. Sato, Y. Awasaki, H. Kandori, Z.-Y. Tanakamaru, H. Nagai, D. Baron, and M. Yamamoto Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats Toxicol. Appl. Pharmacol. 251 2011 234 244
168. M. Schupp, and M.A. Lazar Endogenous ligands for nuclear receptors: digging deeper J. Biol. Chem. 285 2010 40409 40415
169. D.D. Sears, G. Hsiao, A. Hsiao, J.G. Yu, C.H. Courtney, J.M. Ofrecio, J. Chapman, and S. Subramaniam Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization Proc. Natl. Acad. Sci. USA 106 2009 18745 18750
170. D. Shao, S.M. Rangwala, S.T. Bailey, S.L. Krakow, M.J. Reginato, and M.A. Lazar Interdomain communication regulating ligand binding by PPAR-γ Nature 396 1998 377 380
171. S. Singh, Y.K. Loke, and C.D. Furberg Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 298 2007 1189 1195
172. N.-H. Son, T.-S. Park, H. Yamashita, M. Yokoyama, L.A. Huggins, K. Okajima, S. Homma, M.J. Szabolcs, L.-S. Huang, and I.J. Goldberg Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice J. Clin. Invest. 117 2007 2791 2801
173. S.E. Step, H.-W. Lim, J.M. Marinis, A. Prokesch, D.J. Steger, S.-H. You, K.-J. Won, and M.A. Lazar Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers Genes Dev. 28 2014 1018 1028
174. S. Sugii, P. Olson, D.D. Sears, M. Saberi, A.R. Atkins, G.D. Barish, S.-H. Hong, G.L. Castro, Y.-Q. Yin, and M.C. Nelson PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization Proc. Natl. Acad. Sci. USA 106 2009 22504 22509
175. J.M. Suh, J.W. Jonker, M. Ahmadian, R. Goetz, D. Lackey, O. Osborn, Z. Huang, W. Liu, E. Yoshihara, and T.H. van Dijk Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer Nature 2014 10.1038/nature13540 Published online July 16, 2014
176. S. Suzuki, L.L. Arnold, K.L. Pennington, S. Kakiuchi-Kiyota, M. Wei, H. Wanibuchi, and S.M. Cohen Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat Toxicol. Sci. 113 2010 349 357
177. I. Szatmari, E. Rajnavolgyi, and L. Nagy PPARgamma, a lipid-activated transcription factor as a regulator of dendritic cell function Ann. N Y Acad. Sci. 1088 2006 207 218
178. W. Tang, D. Zeve, J. Seo, A.-Y. Jo, and J.M. Graff Thiazolidinediones regulate adipose lineage dynamics Cell Metab. 14 2011 116 122
179. I. Tasdelen, O. van Beekum, O. Gorbenko, V. Fleskens, N.J.F. van den Broek, A. Koppen, N. Hamers, R. Berger, P.J. Coffer, A.B. Brenkman, and E. Kalkhoven The serine/threonine phosphatase PPM1B (PP2Cβ) selectively modulates PPARγ activity Biochem. J. 451 2013 45 53
180. P. Tontonoz, and B.M. Spiegelman Fat and beyond: the diverse biology of PPARgamma Annu. Rev. Biochem. 77 2008 289 312
181. P. Tontonoz, E. Hu, R.A. Graves, A.I. Budavari, and B.M. Spiegelman mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer Genes Dev. 8 1994 1224 1234
182. D. Tripathy, S.C. Clement, D.C. Schwenke, M. Banerji, G.A. Bray, T.A. Buchanan, A. Gastaldelli, R.R. Henry, A.E. Kitabchi, and S. Mudaliar Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW Diabetes Care 37 2014 1706 1711
183. C.-H. Tseng, and F.-H. Tseng Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 30 2012 368 402
184. L.W. Turner, D. Nartey, R.S. Stafford, S. Singh, and G.C. Alexander Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012 Diabetes Care 37 2014 985 992
185. I. Tzoulaki, M. Molokhia, V. Curcin, M.P. Little, C.J. Millett, A. Ng, R.I. Hughes, K. Khunti, M.R. Wilkins, A. Majeed, and P. Elliott Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database BMJ 339 2009 b4731
186. C. Vernochet, S.B. Peres, K.E. Davis, M.E. McDonald, L. Qiang, H. Wang, P.E. Scherer, and S.R. Farmer C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists Mol. Cell. Biol. 29 2009 4714 4728
187. A. von Knethen, N. Tzieply, C. Jennewein, and B. Brüne Casein-kinase-II-dependent phosphorylation of PPARgamma provokes CRM1-mediated shuttling of PPARgamma from the nucleus to the cytosol J. Cell Sci. 123 2010 192 201
188. F. Wang, S.E. Mullican, J.R. DiSpirito, L.C. Peed, and M.A. Lazar Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARγ Proc. Natl. Acad. Sci. USA 110 2013 18656 18661
189. W. Wei, P.A. Dutchak, X. Wang, X. Ding, X. Wang, A.L. Bookout, R. Goetz, M. Mohammadi, R.D. Gerard, and P.C. Dechow Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ Proc. Natl. Acad. Sci. USA 109 2012 3143 3148
190. C. Weidner, J.C. de Groot, A. Prasad, A. Freiwald, C. Quedenau, M. Kliem, A. Witzke, V. Kodelja, C.-T. Han, and S. Giegold Amorfrutins are potent antidiabetic dietary natural products Proc. Natl. Acad. Sci. USA 109 2012 7257 7262
191. R. Wilcox, M.-G. Bousser, D.J. Betteridge, G. Schernthaner, V. Pirags, S. Kupfer, J. Dormandy PROactive Investigators Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) Stroke 38 2007 865 873
192. D. Yamashita, T. Yamaguchi, M. Shimizu, N. Nakata, F. Hirose, and T. Osumi The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain Genes Cells 9 2004 1017 1029
193. J. Yang, C. Vallarino, M. Bron, A. Perez, H. Liang, G. Joseph, and S. Yu A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study Curr. Med. Res. Opin. 2014 10.1185/03007995.2014.941054 Published online July 16, 2014
194. H. Yau, K. Rivera, R. Lomonaco, and K. Cusi The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus Curr. Diab. Rep. 13 2013 329 341
195. J.-M. Ye, N. Dzamko, M.E. Cleasby, B.D. Hegarty, S.M. Furler, G.J. Cooney, and E.W. Kraegen Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin Diabetologia 47 2004 1306 1313
196. T. Yokoi Troglitazone Handb. Exp. Pharmacol. 196 2010 419 435
197. Y.-H. Yoon, and H. Yi Liver Cirrhosis Mortality in the United States, 1970-2009 2012 NIAAA Bethesda, MD
198. H. Zhang, A. Zhang, D.E. Kohan, R.D. Nelson, F.J. Gonzalez, and T. Yang Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention Proc. Natl. Acad. Sci. USA 102 2005 9406 9411